Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | CAR-T in multiple myeloma: cilta-cel & ide-cel

Nikhil Munshi • 9 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT

More from Nikhil Munshi

A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma 2:21
A novel CAR T-cell therapy targeting the intracellular protein MZB1 for multiple myeloma
Nikhil Munshi • 6 Dec 2025
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM 1:44
Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
Nikhil Munshi • 6 Dec 2025
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM 1:32
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi • 19 Oct 2024
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia 1:04
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia
Nikhil Munshi • 19 Oct 2024

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals